Transgene Confirms the Potential of Its Two Innovative Platforms and Expects Sig… – Press Release

[ad_1]

TG4050 (myvac®): First positive results from the two Phase I trials. Additional data to be presented at AACR 2022 in April.

TG4001: First patient enrolled in Phase II study in June 2021. Active patient recruitment in Europe and trial initiation in the US. Interim analysis expected in Q4 2022.

BT-001 (Invir.IO™): IND approval for Phase I/IIa trial in the US, ongoing enrollment in Europe. Next clinical update in Q2 2022.

TG6002: Clinical proof-of-concept of the intravenous administration of an oncolytic virus presented at major congresses in 2021. End of Phase I expected in mid-2022.

AstraZeneca collaboration (Invir.IO™): First option license for an oncolytic virus exercised in 2021. R&D collaboration to develop additional candidates ongoing.

€49.6 million cash available at year-end 2021 providing financial visibility until end of 2023.

Conference call in English scheduled today at 6:00 p.m. CET (details at the end of the release)

Regulatory News:

Transgene TNG TNG, a biotech company that designs and develops virus-based immunotherapies for the treatment of cancer, today publishes its financial results for 2021 and provides an update on its product pipeline.

Hedi Ben Brahim, CEO of Transgene commented: “It has been more than a year since I joined Transgene as Chairman and Chief Executive Officer and I am pleased and proud to have experienced and delivered such a successful year for the Company.

Transgene achieved several important milestones in 2021. We announced the first positive data from two Phase I trials with TG4050, our individualized therapeutic vaccine based on our
myvac® platform. These results demonstrated the immunogenicity of the vaccine, which led to the first signs of clinical activity. We expect to confirm these results in the coming months and to provide more in-depth data at major scientific congresses in 2022.

The Phase II trial with TG4001, our therapeutic vaccine against HPV16-positive anogenital cancers, was launched…

[ad_2]